Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; MChem Chemistry and Drug Discovery, University of Sussex, UK.
Institute of Digestive Disease and the Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
Cancer Lett. 2019 Sep 10;459:186-191. doi: 10.1016/j.canlet.2019.114425. Epub 2019 Jun 8.
The gastrointestinal tract represents one of the largest interfaces between the host and environmental factors. It contains a vast and complex community of microbes, forming what is collectively known as the microbiota. This gut microbiota plays a pivotal role in the maintenance of health, and 'dysbiosis' of the gut microbiota, commonly considered as perturbation of microbiota diversity and composition, has been associated with intestinal and extra-intestinal diseases, including non-alcoholic fatty liver disease (NAFLD) and its associated hepatocellular carcinoma (NAFLD-HCC). In this review, we highlight microbiota dysbiosis and the microbiota-host interactions that link to the pathogenesis of NAFLD and NAFLD-HCC. We discuss the potential therapeutic implications of the gut microbiota in the progression of NAFLD-HCC.
胃肠道是宿主与环境因素之间最大的接口之一。它含有大量且复杂的微生物群落，统称为微生物组。该肠道微生物组在维持健康方面起着关键作用，而肠道微生物组的“失调”通常被认为是微生物多样性和组成的紊乱，与肠道和肠道外疾病有关，包括非酒精性脂肪性肝病（NAFLD）及其相关的肝细胞癌（NAFLD-HCC）。在这篇综述中，我们强调了与 NAFLD 和 NAFLD-HCC 发病机制相关的微生物组失调和微生物组-宿主相互作用。我们讨论了肠道微生物组在 NAFLD-HCC 进展中的潜在治疗意义。
